Comparison of Curcumin Bioavailability
Comparison of the Bioavailability of Different Curcumin Formulations in Healthy Humans
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
- Dietary supplement: Native turmeric extract
- Dietary supplement: Native turmeric extract with 7-9% volatile turmeric oils
- Dietary supplement: Turmeric extract plus mixture of phytochemicals
- Dietary supplement: Cyclodextrin complex of curcuminoids
- Dietary supplement: Turmeric oleoresin
- Dietary supplement: Liposomal curcumin
- Dietary supplement: Phytosomal curcumin
- Dietary supplement: Micellar turmeric extract
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Stuttgart, Baden-Württemberg, Germany, 70599
- University of Hohenheim
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Volunteers with blood chemistry values within normal ranges
- Body mass index in a normal range
Exclusion Criteria:
- Pregnancy or lactation
- Alcohol and or drug abuse
- Use of dietary supplements or any medications except contraceptives
- Any known malignant, metabolic and endocrine diseases
- Previous cardiac infarction
- Dementia
- Blood pressure >140/90 mmHg
- Resting heart rate not within 50 to 90 beats per minute
- Participation in a clinical trial within the past 6 weeks
- Smoking
- Physical activity of more than 5 h per wk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Native turmeric extract
6 capsules of native curcumin (207 mg curcumin)
|
207 mg curcumin
|
|
Experimental: Native turmeric extract with 7-9% volatile turmeric oils
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Turmeric extract plus mixture of phytochemicals
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Cyclodextrin complex of curcuminoids
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Turmeric oleoresin
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Liposomal curcumin
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Phytosomal curcumin
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
|
Experimental: Micellar turmeric extract
6 capsules of the formulation; dosage normalized to 207 mg curcumin
|
207 mg curcumin
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean area under the curve (AUC) of plasma concentration vs. time of total curcumin [nmol/L*h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total curcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Mean area under the curve (AUC) of plasma concentration vs. time of total demethoxycurcumin [nmol/L*h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total demethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Mean area under the curve (AUC) of plasma concentration vs. time of total bisdemethoxycurcumin [nmol/L*h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total bisdemethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Maximum plasma concentration (Cmax) of total curcumin [nmol/L]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total curcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Maximum plasma concentration (Cmax) of total demethoxycurcumin [nmol/L]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total demethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Maximum plasma concentration (Cmax) of total bisdemethoxycurcumin [nmol/L]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total bisdemethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Time to reach maximum plasma concentration (Tmax) of total curcumin [h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total curcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Time to reach maximum plasma concentration (Tmax) of total demethoxycurcumin [h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total demethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
|
Time to reach maximum plasma concentration (Tmax) of total bisdemethoxycurcumin [h]
Time Frame: 0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Total bisdemethoxycurcumin after deconjugation with β-glucuronidase
|
0, 1, 2, 4, 6, 8 and 24 hours post dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jan Frank, Prof. Dr., University of Hohenheim
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Protective Agents
- Antioxidants
- Turmeric extract
- Curcumin
Other Study ID Numbers
Other Study ID Numbers
- HS-CUV-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.